Uptake of tamoxifen in consecutive premenopausal women under surveillance in a high-risk breast cancer clinic

British Journal of Cancer

Volumn 110, Issue 7, 2014, Pages 1681-1687

  Donnelly, L S ^a   Evans, D G ^a,b   Wiseman, J ^a   Fox, J ^a   Greenhalgh, R ^a   Affen, J ^a   Juraskova, I ^c   Stavrinos, P ^d   Dawe, S ^a   Cuzick, J ^e   Howell, A ^a,f  

^a MANCHESTER UNIVERSITY NHS FOUNDATION TRUST   (United Kingdom)

^b ST MARY S HOSPITAL   (United Kingdom)

^c UNIVERSITY OF SYDNEY   (Australia)

^d UNIVERSITY OF MANCHESTER   (United Kingdom)

^e QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^f CHRISTIE HOSPITAL   (United Kingdom)

Author keywords

breast cancer; prevention; qualitative; tamoxifen; uptake

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN; TAMOXIFEN;

ADULT; ARTICLE; BREAST CANCER; CANCER PREVENTION; CANCER RISK; CHEMOPROPHYLAXIS; DRUG EFFICACY; DRUG USE; FEMALE; FOLLOW UP; GENE MUTATION; HEALTH BELIEF; HIGH RISK PATIENT; HUMAN; INTIMACY; MAJOR CLINICAL STUDY; MAMMOGRAPHY; PATIENT DECISION MAKING; PREMENOPAUSE; PRIORITY JOURNAL; QUALITY OF LIFE; SEMI STRUCTURED INTERVIEW; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT;

ADULT; ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; CANCER CARE FACILITIES; DECISION MAKING; FEMALE; HUMANS; INTERVIEWS AS TOPIC; MIDDLE AGED; PREMENOPAUSE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK FACTORS; TAMOXIFEN; WOMEN;

EID: 84897574305     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2014.109     Document Type: Article

References (48)

1. Altschuler A, Somkin CP (2005) Women's decision making about whether or not to use breast cancer chemoprevention. Women Health 41: 81-95.
2. Bastian LA, Lipkus AM, Kuchibhata MN, Weng HH, Halabi S, Ryan PD, Skinner CS, Rimer BK (2001) Women's interest in chemoprevention for breast cancer. Arch Intern Med 161: 1639-1644.
3. Bober SL, Hoke LA, Duda RB, Regan MM, Tung NM (2004) Decision-making about tamoxifen in women at high risk for breast cancer: clinical and psychological factors. J Clin Oncol 22: 4951-4957.
4. Cheng WF, Lin HH, Torng PL, Huang SC (1997) Comparison of endometrial changes among symptomatic tamoxifen-treated and non treated premenopausal and postmenopausal breast cancer patients. Gynecol Oncol 66: 233-237.
5. Cuzick J, Forbes JF, Sestak I, Cawthorn S, Hamed H, Holli K, Howell A, International Breast Cancer Intervention Study I Investigators (2007) Long-term results of tamoxifen prophylaxis for breast cancer-96-month follow-up of the randomized IBIS-I trial. J Natl Cancer Inst 99: 272-282.
6. Cuzick J, Sestak I, Bonanni B, Costantino JP, Cummings S, DeCensi A, Dowsett M, Forbes JF, Ford L, LaCroix AZ, Mershon J, Mitlak BH, Powles T, Veronesi U, Vogel V, Wickerham DL, SERM Chemoprevention of Breast Cancer Overview Group (2013) Selective oestrogen receptor modulators in prevention of breast cancer: an updated meta-analysis of individual participant data. Lancet 381: 1827-1834.
7. Cyrus-David MS, Strom SS (2001) Chemoprevention of breast cancer with selective estrogen receptor modulators: views from broadly diverse focus groups of women with elevated risk for breast cancer. Psychooncology 10: 521-533.
8. Donovan R, Jalleh G, Jones S (2003) The word 'cancer': reframing the context to reduce anxiety arousal. Aust N Z J Public Health 27: 291-293.
9. Evans DG, Harvie M, Bundred N, Howell A (2010) Uptake of breast cancer prevention and screening trials. J Med Genet 47: 853-855.
10. Evans DGR, Lalloo F, Shenton A, Boggis C, Howell A (2001) Uptake of screening and prevention in women at very high risk of breast cancer. Lancet 358: 889-890.
11. Fagerlin A, Zikmund-Fisher BJ, Nair V, Derry HA, McClure JB, Greene S, Stark A, Hensley Alford S, Lantz P, Hayes DF, Wiese C, Claud Zweig S, Pitsch R, Jankovic A, Ubel PA (2010) Women's decisions regarding tamoxifen for breast cancer prevention: responses to a tailored decision aid. Breast Cancer Res Treat 119: 613-620.
12. Fisher B, Costantino JP,Wickerham DL, Cecchini RS, CroninWM, Robidoux A, Kavanah MT, Atkins JN, Margolese RG, Runowicz CD, James JM, Ford LG, Wolmark N (2005) Tamoxifen for the prevention of breastcancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J Natl Cancer Inst 97: 1652-1662.
13. Fisher B, Costantino JP,Wickerham DL, Redmond CK, Kavanah M, Cronin WM, Vogel V, Robidoux A, Dimitrov N, Atkins J, Daly M,Wieand S, Tan-Chiu E, Ford L, Wolmark N (1998) Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 90: 1371-1388.
14. Gail MH, Costantino JP, Bryant J, Croyle R, Freedman L, Helzlsouer K, Vogel V (1999) Weighing the risks and benefits of tamoxifen treatment for preventing breast cancer. J Natl Cancer Inst 91: 1829-1846. Review. Erratum in: J Natl Cancer Inst 2000 92: 275.
15. Goldenberg VK, Seewaldt VL, Scott V, Bean GR, Broadwater G, Fabian C, Kimler B, Zalles C, Lipkus IM (2007) Atypia in random periareolar fine-needle aspiration affects the decision of women at high risk to take tamoxifen for breast cancer chemoprevention. Cancer Epidemiol Biomarkers Prev 16: 1032-1034.
16. Heisey R, Pimlott N, Clemons M, Cummings S, Drummond N (2006) Women's views on chemoprevention of breast cancer: qualitative study. Can Fam Physician 52: 624-625.
17. Juraskova I, Butow P, Lopez A, Seccombe M, Boyle F, McCarthy N, Forbes JF (2007) Improving informed consent to clinical trials: Successful piloting of a decision aid. J Clin Oncol 25: 1443-1444.
18. Kaplan C, Haas J, Perez-Stable EJ, Gregorich S, Somkin C, Des Jarlais G, Kerlikowske K (2006) Breast cancer risk reduction options: discussion, and use among women from four ethnic groups. Cancer Epidemiol Biomark Prev 15: 162-166.
19. Kaplan CP, Kim SE, Wong ST, Sawaya GF, Walsh JME, Perez-Stable EJ (2012) Willingness to use tamoxifen to prevent breast cancer among diverse women. Breast Cancer Res Treat 133: 357-366.
20. Kenen R, Ardern Jones A, Eeles R (2003) Family stories and the use of heuristics: women from suspected hereditary breast and ovarian cancer (HBOC) families. Sociol Health Illn 25: 838-865.
21. Layeequr Rahman R, Crawford S (2009) Chemoprevention Indication Score: a user-friendly tool for prevention of breast cancer-pilot analysis. Breast 18: 289-293.
22. Lippman SM (2006) The dilemma and promise of cancer chemoprevention. Nat Clin Pract Oncol 3: 523.
23. Malek K, Fink AK, Thwin SS, Gurwitz J, Ganz PA, Silliman RA (2004) The relationship among physicians' specialty, perceptions of the risks and benefits of adjuvant tamoxifen therapy, and its recommendation in older patients with breast cancer. Med Care 42: 700-706.
24. McCaskill-Stevens W, Wilson JW, Cook ED, Edwards CL, Gibson RV, McElwain DL, Figueroa-Moseley CD, Paskett ED, Roberson NL, Wickerham DL, Wolmark N (2013) National Surgical Adjuvant Breast and Bowel Project Study of Tamoxifen and Raloxifene trial: advancing the science of recruitment and breast cancer risk assessment in minority communities. Clin Trials 10: 280-291.
25. McIntosh A, Shaw C, Evans G, Turnbull N, Bahar N, Barclay M, Easton D, Emery J, Gray J, Halpin J, Hopwood P,McKay J, Sheppard C, SibberingM, Watson W, Wailoo A, Hutchinson A (2004) Clinical Guidelines and Evidence Review for the Classification and Care of Women at Risk of Familial Breast Cancer. National Collaborating Centre for Primary Care/University of Sheffield NICE guidelineCG041: London, Updated 2006. Available at http://www.nice.org.uk.
26. Meiser B, Butow P, Price M, Bennett B, Berry G, Tucker K, National Consortium for Research into Familial Breast Cancer Psychological Group (2003) Attitudes to prophylactic surgery and chemoprevention in Australian women at increased risk for breast cancer. J Womens Health 12: 769-778.
27. Melnikow J, Paterniti D, Azari R, Kuenneth C, Birch S, Kuppermann M, Nuovo J, Keyzer J, Henderson S (2005) Preferences of women evaluating risks of tamoxifen (POWER) study of preferences for tamoxifen for breast cancer risk reduction. Cancer 103: 1996-2005.
28. Metcalfe KA, Birenbaum-Carmeli D, Lubinski J, Gronwald J, Lynch H, Moller P, Ghadirian P, Foulkes WD, Klijn J, Friedman E, Kim-Sing C, Ainsworth P, Rosen B, Domchek S, Wagner T, Tung N, Manoukian S, Couch F, Sun P, Narod SA. Hereditary Breast Cancer Clinical Study Group (2008) International variation in rates of uptake of preventive options in BRCA1 and BRCA2 mutation carriers. Int J Cancer 122: 2017-2022.
29. Metcalfe KA, Ghadirian P, Rosen B, Foulkes W, Kim-Sing C, Eisen A, Ainsworth P, Horsman D, Maugard C, Provencher D, Robideaux A, Gilchrist D, Chudley A, Lemire EG, Armel S, Finch A, Sun P, Narod SA (2007) Variation in rates of uptake of preventive options by Canadian women carrying the BRCA1 or BRCA2 genetic mutation. Open Med 1: e92-e98.
30. Mulley AG, Sepucha K (2002) Making good decisions about breast cancer chemoprevention. Ann Intern Med 137: 52-54.
31. National Comprehensive Cancer Network (2009) NCCN clinical practice guidelines in oncology: Breast cancer risk reduction, v. 2. http://www.nccn.org.
32. National Institute for Health and Care Excellence (NICE) (2013) Familial breast cancer (CG164): Classification and care of people at risk of familial breast cancer and management of breast cancer and related risks in people with a family history of breast cancer. Issued: June. http://www.nice.org.uk/guidance/ index.jsp?action=byID&o=14188.
33. Port ER, Montgomery LL, Heerd AS, Borgen PI (2001) Patient reluctance toward tamoxifen use for breast cancer primary prevention. Ann Surg Oncol 8: 580-585.
34. Powles TJ, Ashley S, Tidy A, Smith IE, Dowsett M (2007) Twenty-year follow-up of the Royal Marsden randomized, double-blinded tamoxifen breast cancer prevention trial. J Natl Cancer Inst 99: 283-290.
35. Rahman RL, Pruthi S (2012) Chemoprevention of breast cancer: the paradox of evidence versus advocacy inaction. Cancers 4: 1146-1160.
36. Ritchie J, Lewis J (2003) Qualitative Research Practice: A Guide for Social Science Students and Researchers. Sage Publications: London.
37. Rondanina G, Putoni M, Severi G, Varricchio C, Zunino A, Feroce I, Bonanni B, Decensi A (2008) Psychological and clinical factors implicated in decision making about a trial of low-dose tamoxifen in hormone replacement therapy users. J Clin Oncol 26: 1537-1543.
38. Ropka ME, Keim J, Philbrick JT (2010) Patient decisions about breast cancer chemoprevention: a systematic review and meta-analysis. J Clin Oncol 28: 3090-3095.
39. Salant T, Ganschow PS, Olopade OI, Lauderdale DS (2006) Why take it if you don't have anything? Breast cancer risk perceptions and preventive choices at a public hospital. J Gen Intern Med 21: 779-785.
40. Smith A, Moran A, Boyd MC, Bulman M, Shenton A, Smith L, Iddenden R, Woodward ER, Lalloo F, Maher ER, Evans DGR (2007) The trouble with phenocopies: are those testing negative for a family BRCA1/2 mutation really at population risk? J Med Genet 44: 10-15.
41. Taylor R, Taguchi K (2005) Tamoxifen for breast cancer chemoprevention: low uptake by high-risk women after evaluation of a breast lump. Ann Fam Med 3: 242-247.
42. Tchou J, Hou N, Rademaker A, Jordan VC, Morrow M (2004) Acceptance of tamoxifen chemoprevention by physicians and women at risk. Cancer 100: 1800-1806.
43. Tyrer J, Duffy SW, Cuzick J (2004) A breast cancer prediction model incorporating familial and personal risk factors. Stat Med 23: 1111-1130.
44. US Food and Drug Administration (1998) http://www.fda.gov/NewsEvents/ Testimony/ucm115118.htm.
45. Veronesi U, Maisonneuve P, Rotmensz N, Bonanni B, Boyle P, Viale G, Costa A, Sacchini V, Travaglini R, D'Aiuto G, Oliviero P, Lovison F, Gucciardo G, del Turco MR, Muraca MG, Pizzichetta MA, Conforti S, Decensi A, Italian Tamoxifen Study Group (2007) Tamoxifen for the prevention of breast cancer: late results of the Italian Randomized Tamoxifen Prevention Trial among women with hysterectomy. J Natl Cancer Inst 99: 727-737.
46. Visvanathan K, Hurley P, Bantug E, Brown P, Col NF, Cuzick J, Davidson NE, Decensi A, Fabian C, Ford L, Garber J, Katapodi M, Kramer B, Morrow M, Parker B, Runowicz C, Vogel VG, Wade JL, Lippman SM (2013) Use of pharmacologic interventions for breast cancer risk reduction: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol 31: 2942-2962.
47. Waters EA, Cronin KA, Graubard BI, Han PK, Feedman AN (2010) Prevalence of tamoxifen use for breast cancer chemoprevention among US women. Cancer Epidemiol Biomarkers Prev 19: 443-446.
48. Waters EA, McNeel TS, McCaskill Stevens W, Freedman AN (2012) Use of tamoxifen and raloxifene for breast cancer chemoprevention in 2010. Breast Cancer Res Treat 134: 875-880.